Imugene Limited (ASX: IMU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Imugene Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Imugene Limited (ASX: IMU)
Latest News
Healthcare Shares
The Imugene (ASX:IMU) share price has rocketed 80% since August. Here's why
Share Market News
Here are the top 10 ASX shares today
Share Gainers
Why Calix, Imugene, Legacy Iron Ore, and Lovisa shares are charging higher
Healthcare Shares
Imugene (ASX:IMU) share price leaps 9% on Pfizer, Merck deal
Share Market News
Here are the top 10 ASX shares today
Share Market News
Here are the top 10 ASX shares today
Share Gainers
Why Ausnet, Charter Hall, Codan, and Imugene shares are storming higher
Healthcare Shares
Why the Imugene (ASX:IMU) share price is up 9% on Monday
Share Market News
Here are the top 10 ASX shares today
Share Market News
Here are the top 10 ASX shares today
Share Market News
Which ASX 300 shares are the biggest winners and losers on Tuesday?
Share Gainers
Why is the Imugene (ASX:IMU) share price lifting 7% today?
Frequently Asked Questions
-
Imugene does not pay dividends at this stage.
-
Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.
IMU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Imugene Limited
Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.
The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.
The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu.
Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.
